


INFORMAZIONI PERSONALI

Evelina Tacconelli



P.le L.A. Scuro, 10 – 37134 Verona (lavoro)

+39 0458128243

evelina.tacconelli@univr.it

Data di nascita [REDACTED] | Nazionalità Italiana

ESPERIENZA
PROFESSIONALE

10/2017 -	Professore Ordinario Malattie Infettive, Università di Verona
10/2018 -	Direttore Divisione Malattie Infettive, Azienda Ospedaliera Integrata di Verona
10/2018 -	Direttore ID-CARE (Infectious Diseases Center for Translational Research), Università di Verona
01/2021 -	“Lecturer on Antimicrobial Resistance”, Centro Ricerca Clinica DZIF su infezioni associate all’assistenza e resistenza agli antibiotici, Università di Tübingen, Germania
2012 - 2017	Professore Ordinario Malattie Infettive, Università di Tübingen, Germania
2012 - 2020	Direttore Centro Ricerca Clinica DZIF su infezioni associate all’assistenza e resistenza agli antibiotici, Università di Tübingen, Germania
2013-2018	Direttore Medico “Comprehensive Center for infectious Diseases”, Università di Tübingen, Germania
2013-2017	Direttore Divisione Malattie Infettive, Medicina Interna I, Ospedale Universitario di Tübingen, Germania
2003-2007	“Lecturer on Medicine”, Malattie Infettive, BIDMC e Harvard Medical School, Boston, USA
1999-2013	Professore Associato Malattie Infettive, Università Cattolica di Roma
1997-1999	Specialista in Malattie Infettive a contratto Infectious Diseases Specialist, Università Cattolica di Roma

ISTRUZIONE E FORMAZIONE

- Università di Medicina e Chirurgia, Università Cattolica di Roma (09/1986 – 07/1992; 110/110 *cum laude*)
- Specializzazione Malattie Infettive, Università Cattolica di Roma (09/1992 – 07/1996; 60/60 *cum laude*)
- Master in epidemiologia per operatori di sanità pubblica (09/1997 – 07/1998), Università La Sapienza di Roma

ONOREFICENZE,
RICONOSCIMENTI E PREMI

2020	“Lowbury lecture for excellence in research in prevention of healthcare associated infections”, Hospital Infection Society, UK
2004	“Young Investigator Award for Clinical Microbiology and Infectious

	Diseases", European Society of Clinical Microbiology and Infectious Diseases
2003	"Young Investigator Award for the study on antibiotic resistance", Slovak Society of Chemotherapy, Slovakia
1998	"Junior Scholarship Award for curricula studiorum and abstract presentation at 4th International Congress on Drug Therapy in HIV infection", Glasgow, Università di Londra
1997	Borsa di studio per curricula studiorum su AIDS, Istituto Superiore di Sanità

COMITATI REDAZIONALI (selezione)

Since 2020	Senior Editor, Journal of Antimicrobial Chemotherapy
Since 2012	International Advisory Board, Lancet Infectious Diseases
2009-2019	Associated Editor, Journal of Antimicrobial Chemotherapy
2004-2013	Associated Editor, Clinical Microbiology and Infection
Since 2014	Comitato Scientifico, Clinical Microbiology and Infection

SOCIETÀ SCIENTIFICHE & BOARD (selezione)

2021-	Gruppo di lavoro per la coordinazione del piano nazionale per il contrasto all'antimicrobica resistenza (PNCAR, Ministero della Sanità)
2021-	Gruppo di lavoro Linee Guida European Society of Clinical Microbiology and Infectious Disease (ESCMID): Preventive Measures to control COVID-19, Presidente
2021-	ESCMID Gruppo di lavoro Linee Guida: Prevention of surgical site infections, President
2020-	Consulente per la terapia antibiotica Agenzia Italiana Farmaco (AIFA)
2019-	Gruppo Multidisciplinare Regione Veneto per la corretta prescrizione antibiotica (PNCAR, Ministero della Sanità), Presidente
2020	Gruppo di lavoro per l'appropriatezza del ricovero ospedaliero nei pazienti con COVID-19 (AGENAS)
2020-	Comitato tecnico scientifico per l'epidemia da SARS-CoV-2
2019-	OMS Essential Medicine List, Gruppo di lavoro sugli antibiotici
2019	Comitato selettivo "Department of Health and Social Care Antimicrobial Resistance" per l'attribuzione dei progetti di ricerca Sanità Inglese - Research Capital Funding Competition, NHS, UK (Budget da distribuire: £32 million)
2020-	OMS Gruppo di esperti "Identifying Priority Fungal Pathogens"
2017-	ESCMID Gruppo di lavoro Linee Guida: Therapy of multidrug-resistant gram-negative bacteria, Presidente
2018-	Comitato Scientifico di JPI-AMR (Joint Programming Initiative on Antimicrobial Resistance, European Commission)
2015-	EUCIC (European Committee of Infection Control), Presidente
2018-2019	OMS Priority List of antimicrobial resistant bacteria for R&D, Presidente
2009-2017	Education Officer of Infectious Diseases and Clinical

	Microbiology, ESCMID
2017-2019	Guidelines Officer of Infectious Diseases and Clinical Microbiology, ESCMID
2010-	ESCMID Gruppo di lavoro Linee Guida: Infection control of hospital spreading of multidrug-resistant gram-negative bacteria, Presidente
2009-	Consulente per European Center for Diseases Control (ECDC) per la prevenzione delle infezioni ospedaliere ed antibiotico-resistenti
2010-	Consulente OMS sulla terapia e prevenzione delle infezioni resistenti agli antibiotici
2012-2013	External Affair Committee, SHEA (Society of Healthcare Epidemiologists of America)
2016-2019	ESCMID Gruppo di lavoro Linee Guida: decolonisation of multidrug-resistant gram-negative bacteria, Presidenza
2008-2012	ISC (International Society of Chemotherapy) Gruppo di lavoro MRSA, Presidente
2009-2013	Gruppo di Studio sulle infezioni resistenti agli antibiotici della SIMIT (Società Italiana per le Malattie Infettive e Tropicali), Responsabile
Since 2009	Comitato Esecutivo di GISIT (Gruppo Italiano per lo Studio delle Infezioni Ospedaliere)
2012-2013	ESCMID Study Group on Infections in the Elderly (ESGIE), Responsabile
2014-2017	Clinical Advisory Board, HZI (Helmholtz Zentrum für Infektionsforschung, Germania)
2014-2016	Advisory Board, DGI (Deutsche Gesellschaft für Infektiologie, Germania)

PROGETTI DI RICERCA (selezione dal 2010)

Periodo	Studi Nazionali ed Internazionali	Budget, Euro
2020-	Horizon2020 ORCHESTRA: Connecting European cohorts to increase common and effective response to SARS-CoV-2 pandemic	27.779.642
2020-	SENTINELLA: Identificazione rapida della infezione da SARS-CoV-2 nella popolazione generale	737.640
2021-	Cumulative <u>adaptive</u> , <u>multiarm</u> , <u>multistage</u> and multicentre <u>randomized</u> clinical trial with immunotherapy for Moderate COVID-19: the AMMURAVID trial (AIFA), co-PI	60.000
2021-	Horizon2020 ECRAID BASE: European Clinical Research Alliance on Infectious Diseases	999.815
2020-	Horizon2020 EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases	217.047,50
2020-	ENACT: Alliance against COVID-19 (CariVerona)	886.234
2021-	Horizon2020 VACCELERATE: European Corona Vaccine Trial Accelerator Platform - Italian Coordinator	92.361,25

2020-	WHO Solidarity Trial	In-kind contribution (WHO Coordinatore Nazionale)
2021-	Horizon2020 REVERSE: pREvention and management tools for rEducing antibiotic Resistance in high prevalence Settings	2.317.882,50
2007-2011	National Grant (Merck) "Infections caused by <i>enterobacteriaceae</i> producing extended-spectrum β -lactamases in Italy: molecular epidemiology, clinical impact, treatment outcome and risk factors"	300.000
2010-2014	European Grant (7 th Framework) SATURN: Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria	848.000
2010-2013	European Grant DG Sanco Implementing Strategic Bundles for Infection Prevention & Management	87.156
2011-2013	Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for offpatent antibiotics (AIDA) (FP7-HEALTH-2011)	264.640
2011-2013	ECDC Tender: "Producing guidance for prevention and control of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)" (Publication Reference: OJ/12/12/2008 - PROC/2008/045). Germany	In-kind contribution (Esperto)
2012-2013	"Investigator-initiated research grant" (Pfizer): "The burden of bloodstream infections caused by multi-resistant bacteria (MRSA, ESBL) in European hospitals"	40.000
2012-2014	"Is There a Predominance of Gram-Negative Bacterial Bloodstream Infections in Countries with Warmer Climates?"	
2014-2018	DRIVE-AB (IMI-2014): "Driving reinvestment in R&D and appropriate usage of antibiotics"	373.600
2015-	COMBACTE-MAGNET (IMI 2015) "Combating antimicrobial resistance in Europe: new molecules against gram negative bacteria"	4.120.160
2019-	COMBACTE-MAGNET (IMI 2015) "Understanding of the epidemiology and clinical impact of Clostridium difficile infection"	40.000
2012-2020	DZIF (German Center for Infectious Diseases Research) Clinical Trial Unit specialised for research on prevention and treatment of HAIs	1.101.000
2012-2015	"Excellence in Research in Infectious Diseases", University of Tübingen	240.000
2012-2015	DZIF- SPECTRUM- Risk factors for Clostridium difficile at hospital admission",	60.000

	in collaboration with Hamburg University	
2012- 2015	DZIF-ATHOS Antimicrobial stewardship in community and healthcare facilities	63.000
2015-2019	DZIF-BLOOMY Solution for the improvement of bloodstream infections	72.600
2015-2019	DZIF-ABSOLUTE Antimicrobial stewardship to reduce resistance	99.700
2015-2020	DZIF-R-Net Surveillance for antibiotic resistant infections	95.900
2019-	DZIF-PREDICT Validation of the BLOOMY score for mortality	89.900
2016-2017	WHO Tender: Priority list for AMR pathogens for the R&D for new antibiotics	144.000
2016-2019	Sonderlinie Medizin „Perspektive 2020“, Baden-Württemberg: „Surveillance von Mehrfach-Antibiotika-Resistenzen bei Mensch und Tier sowie in der Lebensmittelproduktion in Baden-Württemberg“	340.000
2016-2018	IMI-2016-COMBACTE-MAGNET- ICU-ASPIRE	89.000
2017-2018	WHO Tender: Burden of antibiotic resistant infection (GLASS project)	35.000
2017-2019	JPIAMR: CASE Project: White paper on design of studies on antibiotic stewardship	In-kind contribution (Esperto)
2018-2019	JPIAMR: ARCH Project: Bridging the gap between humAn and animal suRveillance data, antibiotic poliCy, and stewardsHip	50.000
2018-2019	JPIAMR: GAP-One Project: “Global Antimicrobial resistance Platform for ONE Burden Estimates”	In-kind contribution (Esperto)
2018-2019	JPIAMR: CONNECT Project: “inCreasing cOmmunication, awareNEss and data sharing in a global approaCh against resistance”	In-kind contribution (Esperto)
2019	WHO Tender: Duration of antibiotic therapy to treat community acquired pneumonia (EML Unit)	22.000
2019	WHO Tender: Systematic review to develop a WHO Index integrated in the AWARE index to measure optimal antibiotic usage (EML Unit)	21.000
2019-	EXPECT-1 and EXPECT-2 IMI Study: Pilot Study to Assess Success Factors And Barriers for Preparation of a Phase 3 Randomized Controlled Study With ExPEC10V in Adults Aged 60-85 Years With History of Urinary Tract Infection in Stable Health	900.000
2019-2021	BIOSTEPS - AIFA: Personalised surgical prophylaxis in pancreatic surgery in high AMR prevalence	100.000
2019-	CORIS-Veneto region: “Development of a web tool to perform surveillance connected to antibiotic prescription in hospital and community”	210.000
2020-	CORIS-Veneto Region: “Sorveglianza delle infezioni da SARS-CoV-2 nelle	338.000

	scuole e nei luoghi pubblici”	
2018-2020	GARDP – COHERENCE project: Combination tHERapy to treat sepsis due to carbapenem-Resistant bacteria in adult and paediatric population: EvidenCE and common practice	120.000
2018-2020	MODERN Horizon2020: Understanding and modelling reservoirs, vehicles and transmission of ESBL-producing Enterobacteriaceae in the community and long term care facilities	680.000
TOTALE	41 progetti nazionali / internazionali	44.035.008

PUBBLICAZIONI (selezione 2018-2021)

- Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. *Trans R Soc Trop Med Hyg.* 2021 Mar 27
- Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, Tacconelli E. A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. *Infect Dis Ther.* 2021 Mar 9:1–25.
- Adami G, Giollo A, Fassio A, Benini C, Bertoldo E, Bertoldo F, Orsolini G, Idolazzi L, Viapiana O, Giannini S, Passeri G, Tacconelli E, et al. Vitamin D and disease severity in coronavirus disease 19 (COVID-19). *Reumatismo.* 2021 Jan 18;72(4):189-196.
- Bost P, De Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, Trovato R, Caligola S, Lamolinara A, Iezzi M, Facciotti F, Mazzariol A, Gibellini D, De Nardo P, Tacconelli E, et al. Deciphering the state of immune silence in fatal COVID-19 patients. *Nat Commun.* 2021 Mar 5;12(1):1428.
- Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, et al. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. *J Glob Antimicrob Resist.* 2021 Mar 1;25:5-7.
- Theuretzbacher U, Carrara E, Conti M, Tacconelli E. Role of new antibiotics for KPC-producing *Klebsiella pneumoniae*. *J Antimicrob Chemother.* 2021 Jan 29;76(Supplement_1):i47-i54.
- Pezzani MD, Tornimbene B, Pessoa-Silva C, de Kraker M, Rizzardo S, Salerno ND, Harbarth S, Tacconelli E. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. *Clin Microbiol Infect.* 2021 Jan 13:S1198-743X(21)00006-9.
- Riccio ME, Verschuuren T, Conzelmann N, Martak D, Meunier A, Salamanca E, Delgado M, Guthrie J, Peter S, Paganini J, Martischang R, Sauser J, de Kraker MEA, Cherkaoui A, Fluit AC, Cooper BS, Hocquet D, Kluytmans JAJW, Tacconelli E, et al.; MODERN WP2 study group. Household acquisition and transmission of extended-spectrum β -lactamase (ESBL) –producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. *Clin Microbiol Infect.* 2021 Jan 7:S1198-743X(20)30784-9.
- Pezzani MD, Mazzaferri F, Compri M, Galia L, Mutters NT, Kahlmeter G, Zaoutis TE, Schwaber MJ, Rodríguez-Baño J, Harbarth S, Tacconelli E; COACH working group. Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project. *J Antimicrob Chemother.* 2020 Dec 6;75(Suppl 2):ii2-ii19.
- Compri M, Mader R, Mazzolini E, de Angelis G, Mutters NT, Babu Rajendran N, Galia L, Tacconelli E, Schrijver R; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the animal sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6;75(Suppl 2)
- Sibani M, Mazzaferri F, Carrara E, Pezzani MD, Arieti F, Göpel S, Paul M, Tacconelli E, Mutters NT, Voss A; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in long-term care facilities-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6;75
- Pezzani MD, Carrara E, Sibani M, Prestler E, Gastmeier P, Renk H, Kanj SS, Velavan TP, Song LH, Leibovici L, Torumkuney D, Kostyanov T, Mendelson M, Tacconelli E; ARCH working group. White Paper: Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship in the hospital sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6;75(Suppl 2):ii20-ii32.
- Arieti F, Göpel S, Sibani M, Carrara E, Pezzani MD, Murri R, Mutters NT, López-Cerero L, Voss A, Cauda R, Tacconelli E; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6;75(Suppl 2):ii42-ii51. doi:10.1093/jac/dkaa428. PMID: 33280045; PMCID:

- PMC7719405.
- 14: WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb
 - 15: Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, Colombo GL, de Kraker MEA, Essack S, Frost I, Gonzalez-Zorn B, Goossens H, Guardabassi L, Harbarth S, Jørgensen PS, Kanj SS, Kostyanov T, Laxminarayan R, Leonard F, Hara GL, Mendelson M, Mikulska M, Mutters NT, Outtersen K, Baño JR, Tacconelli E, Scudeller L; GAP-ONÉ network. A one health framework to estimate the cost of antimicrobial resistance. *Antimicrob Resist Infect Control*. 2020 Nov
 - 16: Mustafa Hellou M, Górka A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, Poran I, Leeftang MM, Tacconelli E, Paul M. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2021 Mar;27(3):341-351. doi: 10.1016/j.cmi.2020.11.002.
 - 17: Tsioutis C, Birgand G, Bathoom E, Deptula A, Ten Hom L, Castro-Sánchez E, Săndulescu O, Widmer AF, Tsakris A, Pieve G, Tacconelli E, Mutters NT. Education and training programmes for infection prevention and control professionals: mapping the current opportunities and local needs in European countries. *Antimicrob Resist Infect Control*. 2020 Nov 9;9(1):183.
 - 18: Piacentini D, Lanzafame M, Rizzardo S, Chiesi S, Lattuada E, Mehrabi S, Zamboni G, Mazzi R, Tacconelli E, Vento S. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor. *Int J STD AIDS*. 2020 Dec;31(14):1407-1410.
 - 19: Pizzolo F, Rigoni AM, De Marchi S, Friso S, Tinazzi E, Sartori G, Stefanoni F, Nalin F, Montagnana M, Pilotto S, Milella M, Azzini AM, Tacconelli E, Marchi G, Girelli D, Olivieri O, Martinelli N. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. *Thromb Res*. 2020 Oct;194:216-219.
 - 20: Taus F, Salvagno G, Canè S, Fava C, Mazzaferri F, Carrara E, Petrova V, Barouni RM, Dima F, Dalbeni A, Romano S, Poli G, Benati M, De Nitto S, Mansueto G, Iezzi M, Tacconelli E, et al. Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. *Arterioscler Thromb Vasc Biol*. 2020 Dec;40(12):2975-2989.
 - 21: Vehreschild MJGT, Tacconelli E, Giske CG, Peschel A. Beyond COVID-19-a paradigm shift in infection management? *Lancet Infect Dis*. 2020 Oct 9:S1473-3099(20)30789-1.
 - 22: Marchi G, Vianello A, Crisafulli E, Maroccia A, Crinò SF, Pecori S, Zamboni GA, Mazzaferri F, Tacconelli E, Girelli D. Cytomegalovirus-Induced Gastrointestinal Bleeding and Pancreatitis Complicating Severe Covid-19 Pneumonia: A Paradigmatic Case. *Mediterr J Hematol Infect Dis*. 2020 Sep
 - 23: Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Mansueto G. Rapid onset of bronchiectasis in COVID-19 Pneumonia: two cases studied with CT. *Radiol Case Rep*. 2020 Nov;15(11):2098-2103
 - 24: Bielicki JA, Duval X, Gobat N, Goossens H, Koopmans M, Tacconelli E, van der Werf S. Monitoring approaches for health-care workers during the COVID-19 pandemic. *Lancet Infect Dis*. 2020 Oct;20(10):e261-e267.
 - 25: Xanthopoulou K, Peter S, Tobys D, Behnke M, Dinkelacker AG, Eisenbeis S, Falgenhauer J, Falgenhauer L, Fritzenwanker M, Gözl H, Häcker G, Higgins PG, Imirzalioglu C, Käding N, Kern WV, Kramme E, Kola A, Mischnek A, Rieg S, Rohde AM, Rupp J, Tacconelli E, et al.; DZIF R-Net Study Group. Vancomycin-resistant *Enterococcus faecium* colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology. *J Antimicrob Chemother*. 2020 Oct 1;75(10):2743-2751.
 - 26: Deelen JWT, Rottier WC, Giron Ortega JA, Rodriguez-Baño J, Harbarth S, Tacconelli E, Jacobsson G, Zahar JR, van Werkhoven CH, Bonten MJM; ESBL-PREDICT Study Team. An international prospective cohort study to validate two prediction rules for infections caused by 3rd-generation cephalosporin-resistant *Enterobacterales*. *Clin Infect Dis*. 2020 Jul 8:ciaa950.
 - 27: De Nardo P, Gentilotti E, Mazzaferri F, Cremonini E, Hansen P, Goossens H, Tacconelli E; members of the COVID-19MCDA Group. Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage. *Int J Infect Dis*. 2020
 - 28: Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Autenrieth IB, Vehreschild MJGT, Jazmati N, Gerhard M, Stein-Thoeringer CK, Rupp J, Ulm K, Ott A, Lasch F, Koch A, Manns MP, Suerbaum S, Bachmann O. Microbiota-associated risk factors for *C. difficile* acquisition in hospitalized patients: A prospective, multicentric study. *Clin Infect Dis*. 2020 Jun 26:ciaa871.
 - 29: Zuliani S, Zampiva I, Tregnago D, Casali M, Cavaliere A, Fumagalli A, Merler S, Riva ST, Rossi A, Zacchi F, Zaninotto E, Auriemma A, Pavarana M, Soldà C, Benini L, Borghesani M, Caldari A, Casalino S, Gaule M, Kadrija D, Mongillo M, Pesoni C, Biondani P, Cingarlini S, Fiorio E, Melisi D, Parolin V, Tondulli L, Belluomini L, Zecchetto C, Avesani B, Biasi A, Bovo C, Dazzani E, Dodi A, Gelmini S, Leta LC, Lo Cascio G, Lombardo F, Lucin E, Martinelli IA, Messineo L, Moscarda V, Pafumi S, Reni A, Sartori G, Scaglione IM, Shoval Y, Sposito M, Tacconelli E, Trestini I, Zamboni V, Zanelli S, Pilotto S, Milella M. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *Eur J Cancer*. 2020 Aug;135:159-169.
 - 30: Mariotto S, Savoldi A, Donadello K, Zanzoni S, Bozzetti S, Carta S, Zivelonghi C, Alberti D, Piraino F, Minuz P, Girelli D, Crisafulli E, Romano S, Marcon D, Marchi G, Gottin L, Polati E, Zanatta P, Monaco S, Tacconelli E, Ferrari S. Nervous

- system: subclinical target of SARS-CoV-2 infection. *J Neurol Neurosurg Psychiatry*. 2020 Sep;91(9):1010-1012.
- 31: Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, Tacconelli E. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. *Ann Transl Med*. 2020 May;8(9):610. doi:
 - 32: Minuz P, Mansueto G, Mazzaferri F, Fava C, Dalbeni A, Ambrosetti MC, Sibani M, Tacconelli E. High rate of pulmonary thromboembolism in patients with SARS-CoV-2 pneumonia. *Clin Microbiol Infect*. 2020 Nov;26(11):1572-1573.
 - 33: Mehrabi S, Fontana S, Mambrin F, Nguyen HQ, Righi E, Tacconelli E, Mansueto G. Pitfalls of Computed Tomography in the Coronavirus 2019 (COVID-19) Era: A New Perspective on Ground-Glass Opacities. *Cureus*. 2020 May 16;12(5):e8151
 - 34: Savoldi A, Carrara E, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list-authors' response. *J Antimicrob Chemother*. 2020 Jul 1;75(7):2018. doi: 10.1093/jac/dkaa203. PMID: 32459829.
 - 35: Savoldi A, Foschi F, Kreth F, Gladstone BP, Carrara E, Eisenbeis S, Buhl M, Marasca G, Bovo C, Malek NP, Tacconelli E. Impact of implementing a non-restrictive antibiotic stewardship program in an emergency department: a four-year quasi-experimental prospective study. *Sci Rep*. 2020 May 18;10(1):8194. doi:10.1038/s41598-020-65222-7. PMID: 32424172; PMCID: PMC7235006.
 - 36: Niehus R, van Kleef E, Mo Y, Turlej-Rogacka A, Lammens C, Carmeli Y, Goossens H, Tacconelli E, Carevic B, Preotescu L, Malhotra-Kumar S, Cooper BS. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. *Elife*. 2020 May 7;9:e49206. doi: 10.7554/eLife.49206. PMID: 32379042; PMCID: PMC7205461.
 - 37: Anaya-Baz B, Maldonado N, Palacios-Baena ZR, Palomo V, Pezzani MD, Chiesi S, Razzaboni E, Compri M, Tacconelli E, Rodríguez-Baño J. Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol. *BMJ Open*. 2020 May 5;10(5):e030608. doi: 10.1136/bmjopen-2019-030608. PMID: 32371505; PMCID: PMC7228488.
 - 38: Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Schröder W, Peter S, Tacconelli E et al. Prevalence of third-generation cephalosporin-resistant Enterobacterales colonization on hospital admission and ESBL genotype-specific risk factors: a cross-sectional study in six German university hospitals. *J Antimicrob Chemother*. 2020 Jun 1;75(6):1631-1638
 - 39: Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, Thwaites GE. Critical analysis of antibacterial agents in clinical development. *Nat Rev Microbiol*. 2020 May;18(5):286-298.
 - 40: Lo Cascio G, Vincenzi M, Soldani F, De Carolis E, Maccacaro L, Sorrentino A, Nadali G, Cesaro S, Sommariva M, Niero V, Naso L, Grancini A, Azzini AM, Sanguinetti M, Tacconelli E, Cornaglia G. Outbreak of *Saprochaete clavata* Sepsis in Hematology Patients: Combined Use of MALDI-TOF and Sequencing Strategy to Identify and Correlate the Episodes. *Front Microbiol*. 2020 Jan 31;11:84.
 - 41: Birgand G, Mutters NT, Ahmad R, Tacconelli E, Lucet JC, Holmes A; Percept-R Study Group. Risk perception of the antimicrobial resistance by infection control specialists in Europe: a case-vignette study. *Antimicrob Resist Infect Control*. 2020 Feb 14;9(1):33.
 - 42: Shamsrizi P, Gladstone BP, Carrara E, Luise D, Cona A, Bovo C, Tacconelli E. Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. *BMJ Open*. 2020
 - 43: Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, et al. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *Int J Infect Dis*. 2020 Mar;92:62-68.
 - 44: van Rooden SM, Tacconelli E, Pujol M, Gomila A, Kluytmans JAJW, Romme J, Moen G, Couvé-Deacon E, Bataille C, Rodríguez Baño J, Lanz J, van Mourik MSM. A framework to develop semiautomated surveillance of surgical site infections: An international multicenter study. *Infect Control Hosp Epidemiol*. 2020
 - 45: Babu Rajendran N, Mutters NT, Marasca G, Conti M, Sifakis F, Vuong C, Voss A, Baño JR, Tacconelli E; COMBACTE-MAGNET-EPI-Net Consortium. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. *Clin Microbiol Infect*. 2020 Jul;26(7):943.e1-943.
 - 46: Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, Mendelson M, Cappello B, Cooke G, Magrini N; EML Expert Committee and Antibiotic Working Group. Encouraging AwaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. *Lancet Infect Dis*. 2019 Dec;19(12):1278-1280.
 - 47: Babich T, Naucle P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, MacGowan A, Grier S, Chazan B, Yanovskay A, Ami RB, Landes M, Neshet L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, et al. Risk factors for mortality among patients with *Pseudomonas aeruginosa* bacteraemia: a retrospective multicentre study. *Int J Antimicrob Agents*. 2020 Feb;55(2):105847.
 - 48: Savoldi A, Carrara E, Gladstone BP, Azzini AM, Göpel S, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list. *J Antimicrob Chemother*. 2019 Dec 1;74(12):3619-3625.
 - 49: Schweitzer VA, van Werkhoven CH, Rodríguez Baño J, Bielicki J, Harbarth S, Hulscher M, Huttner B, Islam J, Little P, Pulcini C, Savoldi A, Tacconelli E et al; Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Working Group on Design of Antimicrobial Stewardship Evaluations. Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational working group. *Clin Microbiol Infect*. 2020

- Jan;26(1):41-50.
- 50: Chiesi S, Rizzardo S, Piacentini D, Be G, Lattuada E, Tacconelli E, Lanzafame M. Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report. *J Med Case Rep*. 2019 Jul 23;13(1):224.
 - 51: Babich T, Naucier P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskaya A, Ben Ami R, Landes M, Neshet L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, et al. Cefazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite Retrospective Study. *Clin Infect Dis*. 2020 May 23;70(11):2270-2280.
 - 52: Rizzardo S, Lanzafame M, Lattuada E, Luise D, Vincenzi M, Tacconelli E, Vento S. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. *AIDS*. 2019 Aug 1;33(10):1673-1674.
 - 53: Donisi V, Sibani M, Carrara E, Del Piccolo L, Rimondini M, Mazzaferri F, Bovo C, Tacconelli E. Emotional, cognitive and social factors of antimicrobial prescribing: can antimicrobial stewardship intervention be effective without addressing psycho-social factors? *J Antimicrob Chemother*. 2019 Oct 1;74(10):2844-2847.
 - 54: Zingg W, Storr J, Park BJ, Jernigan JA, Harbarth S, Grayson ML, Tacconelli E, Allegranzi B, Cardo D, Pittet D; 2017 Geneva-IPC Think Tank. Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (part 3). *Antimicrob Resist Infect Control*. 2019 May 10;8:74
 - 55: Saris K, Meis JF, Baño JR, Tacconelli E, van de Belt TH, Voss A. Does Online Search Behavior Coincide with *Candida auris* Cases? An Exploratory Study. *J Fungi (Basel)*. 2019 Jun 4;5(2):44
 - 56: Zingg W, Storr J, Park BJ, Ahmad R, Tarrant C, Castro-Sanchez E, Tomczyk S, Kilpatrick C, Allegranzi B, Cardo D, Pittet D; 2017 Geneva IPC-Think Tank. Implementation research for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva infection prevention and control (IPC)-think tank (part 1). *Antimicrob Resist Infect Control*. 2019 May 28;8:87.
 - 57: Zingg W, Park BJ, Storr J, Ahmad R, Tarrant C, Castro-Sanchez E, Perencevich E, Widmer A, Krause KH, Kilpatrick C, Tomczyk S, Allegranzi B, Cardo D, Pittet D; 2017 Geneva IPC-Think Tank. Technology for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva IPC-Think Tank (Part 2). *Antimicrob Resist Infect Control*. 2019 May 22;8:83.
 - 58: Tacconelli E, Górka A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, Huson DH, Carević B, Preoteşcu L, Carmeli Y, Kazma M, Spanu T, Carrara E, Malhotra-Kumar S, Gladstone BP. Estimating the association between antibiotic exposure and colonization with extended-spectrum β -lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study. *Clin Microbiol Infect*. 2020 Jan;26(1):87-94.
 - 59: Tacconelli E, Buhl M, Humphreys H, Malek V, Presterl E, Rodríguez-Baño J, Vos MC, Zingg W, Mutters NT; EUCIC StopNegative group. Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe. *BMJ Open*. 2019 May 19;9(5):e027683.
 - 60: Nicolè S, Lanzafame M, Lattuada E, Luise D, Vecchi M, Tacconelli E, Vento S. Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients. *Infect Dis (Lond)*. 2019 Aug;51(8):615-617.
 - 61: Rizzardo S, Lanzafame M, Lattuada E, Bragantini D, Nicolè S, Calza L, Tacconelli E. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study. *Int J STD AIDS*. 2019 Apr;30(5):467-471.
 - 62: Tacconelli E, Cataldo MA, Mutters NT, Carrara E, Bartoloni A, Raglio A, Cauda R, Mantengoli E, Luzzaro F, Pan A, Beccara LA, Pecile P, Tinelli M, Rossolini GM. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β -lactamase-producing Enterobacteriaceae infections. *Int J Antimicrob Agents*. 2019 Jul;54(1):49-54.
 - 63: Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwab MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. *Clin Microbiol Infect*. 2019 Jul;25(7):807-817. doi: 10.1016/j.cmi.2019.01.005.
 - 64: Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Obermann B, Knobloch JK, Feihl S, Querbach C, Gebhardt F, Mischnik A, Ihle V, Schröder W, Armean S, Peter S, Tacconelli E, et al.; DZIF-ATHOS study group. Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals. *Antimicrob Resist Infect Control*. 2018 Dec 27;7:159.
 - 65: Meletiadis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW. Erratum for Meletiadis et al., "Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone". *Antimicrob Agents Chemother*. 2018 Nov 26;62(12):e02184-18.
 - 66: Schweitzer VA, van Heijl I, van Werkhoven CH, Islam J, Hendriks-Spoor KD, Bielicki J, Bonten MJM, Walker AS, Llewelyn MJ; Consensus on Antimicrobial Stewardship Evaluations (CASE) study group. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. *Clin Microbiol Infect*. 2019 May;25(5):555-561.
 - 67: Dyar OJ, Beović B, Pulcini C, Tacconelli E, Hulscher M, Cookson B; ESCMID generic competencies working group. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus. *Clin Microbiol Infect*. 2019 Jan;25(1):13-19.
 - 68: Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. *Lancet Infect Dis*. 2019 Jan;19(1):4-6.
 - 69: Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae. *Curr Opin Infect Dis*. 2018 Dec;31(6):594-599.
 - 70: Scudeller L, Rodríguez-Baño J, Zinkernagel A, Tacconelli E, Akova M, Friedrich AW, Sanguinetti M, Paul M, Poljak M. ESCMID white paper: a guide on ESCMID guidance documents. *Clin Microbiol Infect*. 2019 Feb;25(2):155-162.

- 71: Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y; DRIVE-AB Consortium. Estimating the number of infections caused by antibiotic-resistant *Escherichia coli* and *Klebsiella pneumoniae* in 2014: a modelling study. *Lancet Glob Health*. 2018 Sep;6(9):e969-e979
- 72: De Backer S, Xavier BB, Vanjari L, Coppens J, Lammens C, Vernu L, Carevic B, Hryniewicz W, Jorens P, Kumar-Singh S, Lee A, Harbarth S, Schrenzel J, Tacconelli E, Goossens H, Malhotra-Kumar S. Remarkable geographical variations between India and Europe in carriage of the staphylococcal surface protein-encoding *sasX/sesI* and in the population structure of methicillin-resistant *Staphylococcus aureus* belonging to clonal complex 8. *Clin Microbiol Infect*. 2019
- 73: Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology*. 2018 Nov;155(5):1372-1382.e17
- 74: Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, et al.; REIPI/ESGBIS/INCREMENT investigators. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. *Int J Antimicrob Agents*. 2018 Nov;52(5):577-585.
- 75: van de Belt TH, van Stockum PT, Engelen LJLP, Lancee J, Schrijver R, Rodríguez-Baño J, Tacconelli E, Saris K, van Gelder MMHJ, Voss A. Social media posts and online search behaviour as early-warning system for MRSA outbreaks. *Antimicrob Resist Infect Control*. 2018 May 30;7:69.
- 76: Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Thoeniger CK, Vehreschild MJGT, Jazmati N, Rupp J, Manns MP, Bachmann O, Suerbaum S. *BaiCD* gene cluster abundance is negatively correlated with *Clostridium difficile* infection. *PLoS One*. 2018 May 8;13(5):e0196977.
- 77: Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, et al.; REIPI/ESGBIS/INCREMENT investigators. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing *Escherichia coli* and ESBL-Producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2018 Jun;39(6):660-667.
- 78: Rohde AM, Wiese-Posselt M, Zweigner J, Schwab F, Mischnek A, Seifert H, Gastmeier P, Kern WV; DZIF-ATHOS Study Group. High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. *J Antimicrob Chemother*. 2018 Jun 1;73(6):1688-1691
- 79: Savoldi A, Azzini AM, Baur D, Tacconelli E. Is there still a role for vancomycin in skin and soft-tissue infections? *Curr Opin Infect Dis*. 2018 Apr;31(2):120-130
- 80: Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outtersen K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018 Mar;18(3):318-327.
- 81: Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, Lucet JC, Moro ML, Tacconelli E, Simonsen GS, Szilágyi E, Voss A, Weber JT. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. *Antimicrob Resist Infect Control*. 2017 Nov 15;6:113
- 82: Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J; EPI-Net COMBACTE-MAGNET Group. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis*. 2018 Mar;18(3):e99-e106.
- 83: Mutters NT, Malek V, Agnandji ST, Günther F, Tacconelli E. Evaluation of the scientific impact of the Ebola epidemic: a systematic review. *Clin Microbiol Infect*. 2018 Jun;24(6):573-576

Verona, 3/4/2021

